About this trial
This study aims to understand how participating in the Western States Endurance Run (WSER), a 100-mile ultramarathon, affects kidney health. Long, strenuous exercise in hot conditions can temporarily strain the kidneys, especially when combined with dehydration, muscle breakdown, and the use of common pain-relief medications such as ibuprofen. Although kidney stress has been reported in endurance sports, no study has examined it directly in runners during the WSER using newer, more sensitive urine markers of kidney injury. Runners who volunteer will complete brief assessments before and after the race. These include providing a urine sample, a small finger-prick blood sample, a body-weight measurement, and answering a short questionnaire about pain-medication use. During the race, participants will wear a global positioning system (GPS) watch and heart-rate strap to monitor effort. Each assessment takes about 15 minutes, and no follow-up is required. Findings from this study will help determine how often kidney stress occurs in this event and what factors may contribute to it, ultimately supporting safer training and medical practices for ultramarathon athletes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Running in the Western States Endurance Run in either 2026, 2027 or 2028
No contraindications to exercise as indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) as prepared by the American College of Sports Medicine (ACSM)
Not currently taking medicine or experiencing illness that may influence the cardiovascular or neuromuscular system
Age ≥18 and ≤ 50 years old and injury free (skeletal muscle) for > 3 months
Disqualifiers
Minors (under 18)
Adults who are unable to consent (impaired decision-making capacity)
Prisoners
Pregnant Women
Trial design
Parallel
Treatments tested in this trial
Sodium Bicarbonate (NaHCO3)
Dietary supplementSB will be used to investigate whether adding a buffer exogenously to aid recovery helps in reducing the severity of acute kidney injury.
Placebo
Dietary supplementThe placebo product consists of the same sodium concentration as the intervention group receiving sodium bicarbonate.
Treatment groups
Trial outcomes
Primary outcomes
Insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)
urine biomarkers of acute kidney injury
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Arizona State University
Lead sponsor
Western States Endurance Run Research Foundation
Collaborator
This trial is not recruiting at the moment. You can still explore other options: